The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Moderna Forging Ahead with mRNA Vaccine Programs for Difficult Viruses; CMV, HIV Jabs in Pipeline: CSO
November 4, 2022
-
ORGANIZATION Priority of Japan Investment Lowered at 27% of Multinational Firms: JPMA Poll
November 2, 2022
-
BUSINESS Average Price Gap for 2023 Revision Looks to Be a Bit Lower than 7.6%: Wholesalers
November 1, 2022
-
REGULATORY Aricept’s Lewy Body Dementia Indication to Be Modified after Post-Launch Trial Miss
October 31, 2022
-
REGULATORY Ex-Bureaucrats, Academics Trade Barbs over Macroeconomic Indexing; Will MOF Allow Rise in Drug Cost?
October 28, 2022
-
ORGANIZATION Japan Needs New Forum for Top-Level Dialogue Including Global CEOs: PhRMA Chair
October 28, 2022
-
BUSINESS Cancer-Savvy New CMO Eager to Extend Astellas’ Oncology Portfolio, Bag Speedy Approval
October 28, 2022
-
REGULATORY Chuikyo to Discuss 2023 Off-Year Re-Pricing with Its Implementation as Premise: MHLW
October 27, 2022
-
REGULATORY LDP to Launch Lawmakers’ League on Medical Adhesive Patches
October 27, 2022
-
REGULATORY Pfizer Assesses Cancer Risk from Amoxan as “Acceptable” at “1 in 200,000 People”
October 26, 2022
-
REGULATORY Commodity Prices Are Rising, That’s Why Full Drug Re-Pricing Needed in 2023: MOF Official
October 25, 2022
-
REGULATORY Moderna’s BA.4/5 COVID Jab Up for PAFSC Review on Oct. 31
October 25, 2022
-
BUSINESS Genmab to Branch Out into 2nd Disease Area beyond Cancer, Specifics to Be Unveiled Next Year: CEO
October 24, 2022
-
ORGANIZATION Over 80% of Wholesaler Reps Say Shipment Adjustments Take Up Most of Their Time: Survey
October 21, 2022
-
REGULATORY With Shortened Interval, Omicron Booster Likely to Cover 18 Million More People by Month-End
October 21, 2022
-
BUSINESS Kyowa Kirin Assigns Bone Metabolism Specialists to Promote Crysvita in Japan
October 20, 2022
-
BUSINESS Sumitomo Aiming to Take the Lead in Developing Universal Flu Vaccines
October 19, 2022
-
BUSINESS Bayer to Distribute Xarelto Tablets 2.5 mg via Single Wholesaler
October 18, 2022
-
REGULATORY Health Ministry Research Team to Vet Recall Rules to Address Supply Disruptions
October 17, 2022
-
BUSINESS Fujifilm Ditches Avigan COVID-19 Program, Pulls Submission in Japan
October 17, 2022
ページ
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…